- 1 Point Sensitivity of the Multi-target Stool DNA Test for Colorectal Cancer Screening in
- 2 Individuals Ages 45-49 Years
- 3
- 4 Michael Domanico, PhD<sup>1</sup>; Sandra Statz, MS<sup>1</sup>; Emily Weiser, MPH<sup>1</sup>; Barry M Berger, MD,
- 5  $FCAP^1$ ; Paul Limburg, MD, MPH<sup>2</sup>
- 6
- <sup>7</sup> <sup>1</sup>Exact Sciences, Madison, WI; <sup>2</sup>Mayo Clinic, Rochester, MN
- 8
- 9 First Author:
- 10 Michael Domanico, PhD
- 11 Product Development
- 12 Exact Sciences Development Company, LLC
- 13 441 Charmany Drive
- 14 Madison, WI 53719
- 15 <u>mdomanico@exactsciences.com</u>
- 16 Sandra Statz, MS
- 17 Clinical and Regulatory Affairs
- 18 Exact Sciences Corporation
- 19 441 Charmany Drive
- 20 Madison, WI 53719
- 21 <u>sstatz@exactsciences.com</u>
- 22 Emily Weiser, MPH
- 23 Medical Affairs
- 24 Exact Sciences Corporation
- 25 441 Charmany Drive
- 26 Madison, WI 53719
- 27 <u>eweiser@exactsciences.com</u>
- 28 Barry M Berger, MD, FCAP
- 29 Medical Affairs
- 30 Exact Sciences Corporation
- 31 441 Charmany Drive
- 32 Madison, WI 53719
- 33 <u>bberger@exactsciences.com</u>
- 34 Corresponding Author:
- 35 Paul Limburg, MD, MPH
- 36 Professor of Medicine
- 37 College of Medicine
- 38 Mayo Clinic
- 39 200 First Street SW
- 40 Rochester, MN 55905
- 41 Tel: (507) 266-4338

2

- 42 Fax: (507) 266-0350
- 43 limburg.paul@mayo.edu
- 44 Word Count: 961
- 45 Pages: 10
- 46 Tables: 1

- 48 Conflicts of Interest: MD, SS, and EW are employees of Exact Sciences. BMB is a clinical
- 49 consultant to and equity holder of Exact Sciences. PL serves as Chief Medical Officer for
- 50 Screening at Exact Sciences through a contracted services agreement with Mayo Clinic. Dr.
- 51 Limburg and Mayo Clinic have contractual rights to receive royalties through this agreement.
- 52 Financial Disclosures: This study was funded by Exact Sciences (Madison, WI).
- 53 Other Acknowledgments: Medical writing and editorial support was provided by Rebecca K
- 54 Swartz, PhD, an employee of Exact Sciences (Madison, WI).

3

### 55 Abstract

Background: Most colorectal cancer (CRC) screening tests have not been rigorously studied in
younger age groups.

Aims: To estimate sensitivity of the multi-target stool DNA (mt-sDNA) test in patients ages 45-

59 49 years.

60 Methods: We identified archived stool samples (Exact Sciences; Madison, WI) from individuals

ages 45-49 years who had completed an index colonoscopy and had confirmed diagnoses of

62 CRC or advanced precancerous lesions (APL; defined as high-grade dysplasia, >25% villous

63 morphology, or  $\geq 1$  cm in size [conventional adenoma or serrated lesion]). Data annotation

referent to potential CRC risk factors, other than age, was limited. Stool samples were collected

at least 7 days after the index colonoscopy, prior to lesion excision or treatment. Stool samples

66 were processed and analyzed per established laboratory protocols for the mt-sDNA assay. Mt-

sDNA test sensitivity for CRC, APL, and CRC+APL was estimated from the available sample

68 set. Samples were collected from 2010-2013 (NCT01260168) and 2014-2017 (NCT02503631),

69 with sample testing and analysis in 2019.

70 Results: Stool samples were analyzed from 19 eligible subjects, 13 with CRC and

6 with APL. Estimated mt-sDNA test sensitivity for CRC, APL, and CRC+APL were 92%, 83%,
and 89%, respectively.

73 Conclusions: In this small pilot study using existing archived stool samples from subjects ages

45-49 years, mt-sDNA test sensitivity was similar to previously reported estimates for

individuals ages  $\geq$ 50 years. These results support the application of mt-sDNA screening to

- 4
- 76 average-risk patients beginning at age 45 years. Larger studies are needed to confirm and extend
- 77 these findings.
- 78 Keywords
- 79 Early detection of cancer; colorectal neoplasms; colorectal cancer screening; colorectal cancer
- 80 prevention
- 81

5

## 82 Introduction

83	Colorectal cancer (CRC) is the fourth most-diagnosed cancer and second deadliest cancer in the
84	United States.[1] Although CRC incidence and mortality rates in the $\geq$ 55-year-old population are
85	decreasing, CRC incidence and mortality rates are increasing in those <55 years of age.[2] In
86	2020, 17,930 new CRC cases and 3640 deaths are estimated in individuals <50 years-old.[3] The
87	American Cancer Society (ACS) CRC screening guidelines now recommend initiating CRC
88	screening at age 45 years for individuals at average risk for CRC, whereas previous iterations of
89	the guidelines recommended initiating screening at age 50 for most average-risk individuals.[4]
90	The endorsed CRC screening test options remained unchanged in the older and younger
91	populations. However, most endorsed CRC screening tests have not been rigorously evaluated in
92	individuals <50 years of age.
93	
94	One ACS-recommended CRC screening option is the multi-target stool DNA (mt-sDNA) test.
95	The mt-sDNA test was approved by the US Food and Drug Administration (FDA) in 2014 to
96	screen individuals ≥50 years at average risk for CRC and was granted an FDA label expansion in
97	2019 to screen average-risk individuals beginning at age 45 years. In a study of nearly 10,000
98	participants $\geq$ 50 years at average risk for CRC, the mt-sDNA test was 92% sensitive for CRC,
99	42% sensitive for advanced precancerous lesions (APL), and 87% specific, including participants
100	with nonadvanced adenomas (NAA) or negative findings on colonoscopy.[5]
101	
102	Although existing data do not suggest age-related changes in sensitivity of the mt-sDNA test,[5]

103 further investigation is needed to more fully define the mt-sDNA test performance for average-

6

risk CRC screening in individuals 45-49 years of age. In this study, we examined the point
sensitivity of the multi-target stool DNA (mt-sDNA) test, using archived stool samples from
patients ages 45-49 years and with confirmed CRC or APL.

107

- 108 Methods
- 109 *Study Samples*

110 The Exact Sciences (Madison, WI) biorepository was queried to identify archived stool samples 111 previously collected (NCT01260168, NCT02503631), prepared for stool DNA testing, and 112 stored at -80°C from individuals ages 45-49 years who underwent an index colonoscopy with 113 confirmed diagnosis of CRC or APL. APL were defined as neoplasia with high-grade dysplasia 114 or  $\geq 25\%$  villous morphology, or conventional adenomas or serrated lesions  $\geq 1$  cm in size. Data 115 annotation referent to potential CRC risk factors, other than age, were not systematically collected from subjects with archived stool samples and were, therefore, limited. Stool samples 116 117 were collected at least 7 days after the index colonoscopy, prior to lesion excision or treatment. Stool samples were processed and analyzed per established laboratory protocols for the mt-118 sDNA assay. Additionally, data from previously tested stool samples collected from individuals 119 120 ages 45-49 years were identified and included in the analyses. Stool samples were collected from 2010 to 2013 (NCT01260168) and 2014 to 2017 (NCT02503631) during studies approved by the 121 122 Copernicus Group Institutional Review Board. Use of the samples for the current study was 123 covered in the original informed consent. Sample testing and retrospective analyses occurred in 2019. 124

7

### 126 *Measures*

127	Mt-sDNA test point sensitivity estimates for CRC, APL, and advanced colorectal neoplasia
128	(CRC+APL) were defined as the primary study endpoints.
129	
130	Statistical Analysis
131	The number and percent of positive mt-sDNA test results were summarized for each neoplasia
132	outcome of interest. Given the limited availability of archived stool samples from subjects who
133	met the eligibility criteria, this pilot study was not powered for more robust statistical analyses.
134	
135	Results
136	Previously tested and archived samples were available from a total of 19 eligible subjects,
137	including 13 with CRC and 6 with APL. The average size of index lesions was 3 cm; however,
138	lesion size was missing from 3 samples. Mt-sDNA test sensitivity was 92% for CRC, 83% for
139	APL, and 89% for advanced colorectal neoplasia (CRC+APL) (Table 1).
140	
141	Discussion
142	Data from this relatively small, pilot study using existing, archived stool samples from
143	individuals ages 45-49 years with clinically confirmed CRC or APL demonstrate high point
144	sensitivity of the mt-sDNA test for advanced colorectal neoplasia (89%). While CRC sensitivity
145	at 92% was similar to previously reported estimates for individuals ages 50 years and older, APL

sensitivity at 83% exceeded that seen previously in individuals  $\geq$ 50 years,[5] though this is based

8

147	on a small, convenience sample of archived stool specimens. This study provides an initial
148	demonstration of mt-sDNA test sensitivity in this younger population, which supports the recent
149	label expansion to extend the application of this test to average-risk CRC screening for
150	individuals ages 45 and older. Of note, a large, prospective clinical trial (NCT03728348) to
151	assess specificity of the mt-sDNA test in individuals 45-49 years-old was recently completed and
152	will further define the mt-sDNA test performance in this younger age group.

153

#### 154 *Limitations*

155 The major limitation of this pilot study is the relatively small sample size, which was determined 156 primarily by the availability of existing, archived stool specimen data. Since the mt-sDNA test 157 was originally approved for CRC screening in average-risk patients  $\geq$ 50 years, stool samples 158 have not been frequently collected from younger patients for molecular marker interrogation in 159 routine clinical practice. As such, more comprehensive data analyses were not feasible for this 160 initial investigation of mt-sDNA test sensitivity due to limited statistical power. Additionally, the average index lesion size in this study (3 cm) was larger than would be expected in a typical 161 CRC screening population. This may overestimate the sensitivity compared to an average-risk 162 163 screening population. Nonetheless, based on the analyzed samples, mt-sDNA test sensitivity was 164 similar to previously reported data for individuals 50 years and older at average risk for CRC, [5] 165 supporting the expectation of comparable test sensitivity in this younger population, which will 166 be further clarified by forthcoming data from additional studies.

167 The mt-sDNA test demonstrated high point sensitivity for advanced colorectal neoplasia in stool

samples from patients ages 45-49 years, supporting its application as a widely accessible,

169 noninvasive option for average-risk CRC screening in this age group.

#### 9

### 170 **References**

- American Cancer Society. Cancer Facts & Figures 2020: (2020, accessed January 21,
   2020).
- 173 2. Siegel R, Fedewa SA, Anderson WF, et al. Colorectal Cancer Incidence Patterns in the
- 174 United States, 1974-2013. *Journal of the National Cancer Institute*. 2017; 109.
- 175 3. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA
- 176 *Cancer J Clin.* 2020.
- 177 4. American Cancer Society. American Cancer Society Guideline for Colorectal Cancer
- 178 Screening. Atlanta: American Cancer Society, 2018.
- 179 5. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget Stool DNA Testing for
- 180 Colorectal-Cancer Screening. *The New England journal of medicine*. 2014; 370: 1287-97.

# 181 Tables

# 182 Table 1. Point Sensitivity of the mt-sDNA Test for Colorectal Cancer, Advanced Precancerous

183

## Lesions, and Advanced Colorectal Neoplasia

	Total Cases	Positive (N)	Point Sensitivity (%)				
CRC	13	12	92				
APL	6	5	83				
ACN (CRC+APL)	19	17	89				
ACN – advanced colorectal neoplasia; APL – advanced precancerous lesions; CRC – colorectal cancer.							